Navigation Links
Apex Bioventures Acquisition Corporation Receives Notice of Extension from NYSE Amex
Date:5/11/2009

HILLSBOROUGH, Calif., May 11 /PRNewswire-FirstCall/ -- Apex Bioventures Acquisition Corporation (NYSE Amex: PEX) (the "Company") announced today that it has received notice from NYSE Amex LLC (the "Exchange") that the plan of compliance submitted by the Company has been accepted by the Exchange and the Company has been granted an extension until August 11, 2009 to regain compliance with the continued listing standards of the Exchange.

As reported in a press release dated February 13, 2009, the Company received notice from the Exchange on February 10, 2009 indicating that the Company is not in compliance with one of the requirements for continued listing on the Exchange due to the Company's failure to hold an annual meeting during calendar year 2008. The Company was afforded the opportunity to submit to the Exchange a plan of compliance and on March 6, 2009, submitted its plan to the Exchange.

The Company will be subject to periodic review by Exchange staff during the extension period. Failure to make progress consistent with the plan or to regain compliance with the continued listing standards by the end of the extension period could result in the Company being delisted from the Exchange.

Forward-Looking Statements

This press release contains certain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. These statements are based on current expectations and are subject to numerous risks, assumptions and uncertainties, many of which change over time and are beyond the Company's control. Actual results may differ materially from those anticipated in any forward-looking statement and you should not place any undue reliance on such forward-looking statements. More detailed information about the Company and risk factors that may affect the realization of forward-looking statements, including forward-looking statements in this press release, is set forth in the Company's filings with the Securities and Exchange Commission. The Company urges investors and security holders to read those documents free of charge at the Commission's web site at http://www.sec.gov. Interested parties may also obtain these documents free of charge from the Company. Forward-looking statements speak only as to the date they are made, and except for any obligation under the U.S. federal securities laws, the Company undertakes no obligation to publicly update any forward-looking statement as a result of new information, future events or otherwise.


'/>"/>
SOURCE Apex Bioventures Acquisition Corporation
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Newbridge Securities Corporation Forms BioVentures Division
2. Lorus Therapeutics Announces Exclusive Multinational License Agreement with Zoticon Bioventures for Virulizin(R)
3. CRO Acquisition Seen Boosting Activity, Positioning ASG, Inc., for New Growth in Q2
4. China Biologic Products Completes Acquisition of 90% Controlling Interest in Chongqing Dalin Biologic Technologies Co., Ltd.
5. Gen-Probe Completes Acquisition of Tepnel Life Sciences
6. China Biologic Products Completes Acquisition of 35% Interest in Xian Huitian Blood Products Co., Ltd.
7. RoundTable Healthcare Partners Facilitates Product Acquisition for CorePharma
8. JAG Media Holdings, Inc. Announces Letter of Intent for the Acquisition of CardioGenics Inc. by a Wholly-Owned Subsidiary of JAG Media
9. Covance Increases Early Clinical Footprint in Europe with Acquisition of Swiss-Based Early Clinical Development Site
10. BVF Acquisition LLC Extends Avigen Tender Offer to April 3, 2009
11. Morningstar Healthcare Analysts to Discuss Top 15 Biotech Acquisition Targets on Wednesday, March 4 at 11 a.m. EST
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/28/2017)... Oakland, California (PRWEB) , ... March 28, 2017 , ... ... that its flagship product, AllegroGraph , has been named a ‘Champion’ by Bloor ... “AllegroGraph is the highest ranked product in its class, and, thanks to Gruff, it ...
(Date:3/28/2017)... WASHINGTON , March 28, 2017  (AACR17, Booth ... sequencing during the American Association for Cancer Research (AACR) ... in Washington, D.C. , April 1-5, ... expression of thousands of cells at the individual level. ... Experts on-hand at AACR to discuss expanded next ...
(Date:3/28/2017)... HOLLISTON, Mass. , March 28, 2017 ... "Company"), a biotechnology company developing bioengineered organ implants to ... bronchus and trachea, today announced that Jim McGorry, ... 3D Printing and BioEngineering panel at the ... 2017 at 2:30 PM ET in Cambrige, Massachussetts. The ...
(Date:3/28/2017)... 2017 /PRNewswire/ -RepliCel Life Sciences Inc. (OTCQB: REPCF) (TSXV: RP) ... safety and clinical data from its phase 1/2 tendon repair ... follicle-derived fibroblasts (RCT-01) as a treatment for Achilles tendinosis. ... The ... profile at 6 months and showed no serious adverse events ...
Breaking Biology Technology:
(Date:2/28/2017)... , Feb. 28, 2017   Acuant , a ... globally, announces significant enhancements to new and core technologies ... New products include mobile and desktop Acuant FRM TM ... - a real time manual review of identity ... technology provides the fastest and most accurate capture software ...
(Date:2/26/2017)... -- Securus Technologies, a leading provider of civil and ... corrections and monitoring, announces the appointment of a ... often, too many offenders return to jail or ... to tackle this ongoing problem and improve the ... significant steps are underway, Securus continues to invest ...
(Date:2/21/2017)... -- Der weltweite Biobanking-Sektor wird bis zum ... mit mehr als 50 Vertretern aus verschiedenen Branchen wurde aber ... diese Prognose zu realisieren. ... Zu den Schwierigkeiten für ... für die Biobank, die Implementierung Zeit sparender Technologien, ein ...
Breaking Biology News(10 mins):